[go: up one dir, main page]

AU2003250685A8 - Methods of identifying selective beta-1-adrenergic receptor antagonists - Google Patents

Methods of identifying selective beta-1-adrenergic receptor antagonists

Info

Publication number
AU2003250685A8
AU2003250685A8 AU2003250685A AU2003250685A AU2003250685A8 AU 2003250685 A8 AU2003250685 A8 AU 2003250685A8 AU 2003250685 A AU2003250685 A AU 2003250685A AU 2003250685 A AU2003250685 A AU 2003250685A AU 2003250685 A8 AU2003250685 A8 AU 2003250685A8
Authority
AU
Australia
Prior art keywords
methods
receptor antagonists
adrenergic receptor
selective beta
identifying selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250685A
Other versions
AU2003250685A1 (en
Inventor
Youngshil Pak
Daniela Rotin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Original Assignee
Hospital for Sick Children HSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children HSC filed Critical Hospital for Sick Children HSC
Publication of AU2003250685A8 publication Critical patent/AU2003250685A8/en
Publication of AU2003250685A1 publication Critical patent/AU2003250685A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
AU2003250685A 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists Abandoned AU2003250685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,396,350 2002-07-31
CA002396350A CA2396350A1 (en) 2002-07-31 2002-07-31 Methods of identifying selective .beta.-1-adrenergic receptor antagonists
PCT/CA2003/001130 WO2004011018A2 (en) 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists

Publications (2)

Publication Number Publication Date
AU2003250685A8 true AU2003250685A8 (en) 2004-02-16
AU2003250685A1 AU2003250685A1 (en) 2004-02-16

Family

ID=30774592

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250685A Abandoned AU2003250685A1 (en) 2002-07-31 2003-07-31 Methods of identifying selective beta-1-adrenergic receptor antagonists

Country Status (3)

Country Link
AU (1) AU2003250685A1 (en)
CA (1) CA2396350A1 (en)
WO (1) WO2004011018A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031955A2 (en) 2004-09-14 2006-03-23 The Regents Of The University Of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
CN112575051A (en) * 2019-09-27 2021-03-30 泰州医药城国科化物生物医药科技有限公司 Cell screening model of beta 1 adrenergic receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203776B1 (en) * 1997-04-03 2001-03-20 University Technology Corporation Method for identifying adrenergic receptor antagonists having good tolerability
CA2259830A1 (en) * 1999-01-20 2000-07-20 Hsc Research And Development Limited Partnership Ras activator nucleic acid molecules, proteins and methods of use

Also Published As

Publication number Publication date
WO2004011018A2 (en) 2004-02-05
CA2396350A1 (en) 2004-01-31
AU2003250685A1 (en) 2004-02-16
WO2004011018A3 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
NO20051871D0 (en) Opioid receptor antagonists
IL165871A0 (en) Substituted quinoline CCR5 receptor antagonists
IL165841A0 (en) Mchir antagonists
ZA200408342B (en) Tricyclic thrombin receptor antagonists
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
IL162825A0 (en) Fluoro substituted cycloalkanoindoles and their use asprotaglandin d2 receptor antagonists
AU2003231513A1 (en) Pgd2 receptor antagonist
GB2384796B (en) Shaped pad for downhole formation testing
PL378753A1 (en) Ccr-3 receptor antagonists
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
IL163939A0 (en) Nk1 antagonists
IL176350A0 (en) Crf receptor antagonists and methods relating thereto
EP1631559A4 (en) Il-8 receptor antagonists
AU2003260072A8 (en) Antagonists of chemokine receptors
IL165727A0 (en) Chemokine antagonists
AU2003267088A8 (en) Chemokine receptor antagonists as therapeutic agents
AU2003300904A8 (en) Antagonists for human prolactin
AU2003240705A1 (en) Morpholinylmethylureas ccr-3 receptor antagonists
GB0203412D0 (en) 5-HT 2B receptor antagonists
GB0226227D0 (en) Receptors
AU2003280675A1 (en) SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT
AU2002359524A8 (en) P2x7 receptor antagonists
AU2003287219A8 (en) Il-8 receptor antagonists
AU2003250685A8 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
EP1636230A4 (en) A1 adenosine receptor antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase